ClinicalTrials.gg
RecruitingNCT05851092Updated Jul 7, 2023

Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors

A Phase 1 interventional study of HRS-2189 Tablets in Advanced Malignant Tumor, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-07.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multi center, open label, dose increasing/dose expanding/efficacy expanding phase I clinical trial aimed at evaluating the safety, tolerance, PK characteristics, and anti-tumor efficacy characteristics of HRS-2189 single drug in patients with advanced malignant solid tumors. This study was divided into three stages: dose escalation, dose expansion, and efficacy expansion.

02

Conditions studied

  • Advanced Malignant Tumor
03

In context

Lead sponsor

Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer to participate in this study, sign an form, have good compliance, and can cooperate with follow-up
  2. Age ≥ 18 years old (including boundary value, calculated based on the date of signing informed consent), Male or female
  3. score: 0-1
  4. Expected survival ≥ 12 weeks
  5. Local recurrent or advanced malignant solid tumor confirmed by histopathology or cytopathology and not resectable, and currently fails to undergo standard treatment or has no standard treatment plan
  6. If enrolled in ER positive and negative female breast cancer subjects, they need to meet the criteria defined in the guidelines of the American Association of Clinical Oncology/American College of Pathologists
  7. Baseline presence of at least one extracranial that meets the v1.1 standard
  8. The functional level of important organs is basically normal, meeting the requirements of the scheme
  9. Previous treatment: Before the first medication in this study, the interval between receiving nitrosourea or mitomycin C ≥ 6 weeks; Receiving cytotoxic drugs, endocrine therapy, immunotherapy, targeted therapy, surgical interval (except puncture or PICC catheterization or PORT infusion port catheterization) or other clinical studies with the last medication ≥ 4 weeks; Interval from the end of radiotherapy ≥ 2 weeks
  10. Adverse events caused by other treatments for the subject returned to a severity level of V5.0 ≤ 1 (excluding hair loss and other adverse events judged tolerable by the investigator)
  11. Female subjects with fertility must agree to use highly effective during the study treatment period and within 7 months after the last medication; Male subjects must agree to use highly effective contraception during the study treatment period and 4 months after the last medication; Female subjects with fertility must have a negative serum HCG test within 7 days before the first medication in the study, and must be in non lactation. If the serum HCG is weakly positive, it is necessary for the researcher to evaluate and judge it as a non pregnant state, and urine HCG should be tested before medication, with a negative result
  12. Volunteer to participate in this clinical trial, willing and able to follow the procedures related to clinical visits and research, understand the research procedures, and have signed informed consent

Exclusion criteria

Exclusion Criteria:

  1. Subjects with cancerous meningitis or untreated central nervous system
  2. Uncontrolled pleural, abdominal, and pericardial effusion
  3. Clinical symptoms or diseases of the heart that are not well controlled
  4. Arterial/venous thrombotic events occurred within 6 months before the first medication administration
  5. Active infection or unexplained fever>38.5 ° C occurred within 4 weeks before or on the day of the first medication (subjects with tumor fever are judged by the investigator to be included in the study)
  6. Subjects with congenital or acquired immune dysfunction (such as infected persons); Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation
  7. Subject has active hepatitis
  8. Subjects had other malignant tumors within the past 3 years, except for fully treated basal or squamous cell skin cancer or cervical carcinoma in situ
  9. Those who are unable to swallow tablets normally or have gastrointestinal dysfunction that may affect drug absorption according to the judgment of the researcher
  10. Patients participating in the /QTc study have used any medication that has the risk of prolonging the QT/QTc interval or causing torsade de pointe (TdP) within 4 weeks before the first medication, have a previous history of congenital QT interval prolongation syndrome or a family history of QT interval prolongation, have an implanted pacemaker or automatic implantable cardioverter defibrillator, and cannot correct electrolyte disturbances that affect the QT/QTc study
  11. Pregnant and lactating women, or planning to become pregnant during the study period
  12. According to the judgment of the researcher, the subject has other factors that may lead to the forced termination of this study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    HRS-2189 Tablets

    Drug: HRS-2189 Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. AEs+SAEs

    Time frame: from the first drug administration to within 30 days for the last treatment dose

  2. Dose limited toxicity (DLT) of HRS-2189

    Time frame: up to 35 days

  3. Maximum tolerated dose(MTD)of HRS-2189

    Time frame: up to 35 days

  4. Recommended Phase II Dose (RP2D) of HRS-2189

    Time frame: up to 35 days

Secondary outcomes

  1. Evaluation of pharmacokinetic parameter of HRS-2189: Cmax

    Time frame: 2 months

  2. Evaluation of pharmacokinetic parameter of HRS-2189: Tmax

    Time frame: 2 months

  3. Evaluation of pharmacokinetic parameter of HRS-2189: AUC0-t

    Time frame: 2 months

  4. Evaluation of pharmacokinetic parameter of HRS-2189: AUC0-inf

    Time frame: 2 months

  5. Evaluation of pharmacokinetic parameter of HRS-2189: Cmax,ss

    Time frame: 2 months

  6. Evaluation of pharmacokinetic parameter of HRS-2189: Tmax,ss

    Time frame: 2 months

  7. Evaluation of pharmacokinetic parameter of HRS-2189: Cmin,ss

    Time frame: 2 months

  8. Evaluation of pharmacokinetic parameter of HRS-2189: AUCss

    Time frame: 2 months

  9. Evaluation of pharmacokinetic parameter of HRS-2189: Rac

    Time frame: 2 months

  10. Bioavailability of HRS-2189 on an empty stomach and after meals

    Time frame: up to 9 days

  11. Objective Response Rate (ORR)

    Number of responders Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) for target lesions assessed by CT or MRI

    Time frame: every 8 weeks since Day 8 administration,an average of 1 year

  12. Duration of response (DoR)

    Time from documentation of tumor response to disease progression assessed among patients who had an objective response

    Time frame: every 8 weeks since Day 8 administration,an average of 1 year

  13. Disease control rate (DCR)

    Complete response + Partial response + Stable disease (CR+PR+SD) based on RECIST 1.1

    Time frame: every 8 weeks since Day 8 administration,an average of 1 year

  14. Progression free survival(PFS)

    The time from enrollment to the progression of tumors (in any aspect) or death (for any reason)

    Time frame: every 8 weeks since Day 8 administration,an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
    Recruiting
    • Qingyuan Zhang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Dec 2025, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 9, 2023
StartActual
May 26, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jul 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05851092
Responsible party
Sponsor
First posted
May 9, 2023
Start date
May 26, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jul 7, 2023

Study contacts

Xia Zhang
Contact
xia.zhang@hengrui.com
+86-0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-2189

Start the discussion